More convenient format for media fill broth
Animal-free media fill broth is now available in ready-to-use bags
The BPCs are manufactured from a medical grade plastic film that meets USP Class VI requirements and are certified free from animal-derived components. Connection is made through a male or female connector that is attached to the BPC with C-Flex tubing.
Oxoid cfVPB is also certified free from animal-derived components, making it ideal for production environments in the pharmaceutical industry, where there is a need to control the risk of contamination from animal-derived materials–particularly with the emergence of diseases such as transmissible spongiform encephalopathies (TSE).
‘BPC’s provide an efficient means for companies to save time and resources,’ said Maria Higgins, pharmaceutical applications manager, Oxoid products. ‘The containers reduce waste and lower cleaning costs. Moreover, the BPCs minimise the risk of cross-contamination, allowing companies to meet regulatory standards.’ says the company.
The cfVPB is gamma-irradiated at a dose validated to be lethal for all yeasts, moulds and bacteria, including bacterial spores and mycoplasmas. The BPCs are, likewise, gamma-irradiated. The medium is prepared using water-for-injection–quality water. The BPCs are aseptically filled, ensuring that the prepared medium is suitable for use in pharmaceutical clean room support areas. The product is also accompanied with quality certification providing full traceability for each batch.
The broth is available as standard in 10 and 20 litre volume BPCs; other sizes are custom-made.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Accelerating the development of bispecific antibodies
Read moreSherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Accelerating the development of bispecific antibodies
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Regulatory
UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead
The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Regulatory
Lonza Nominates Stephen Fry as Independent Board Member
Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
Manufacturing
Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform
The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering